The positive effect of short-term nano-curcumin therapy on insulin resistance and serum levels of afamin in patients with metabolic syndrome | ||
Avicenna Journal of Phytomedicine | ||
دوره 11، شماره 2، خرداد و تیر 2021، صفحه 146-153 اصل مقاله (439.86 K) | ||
نوع مقاله: Original Research Article | ||
شناسه دیجیتال (DOI): 10.22038/ajp.2020.16698 | ||
نویسندگان | ||
Nejat Kheiripour1؛ Zahra Khodamoradi2؛ Akram Ranjbar3؛ Shiva Borzouei* 4 | ||
1Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran | ||
2Student Research Committee, Hamadan University of Medical Sciences, Hamadan, Iran | ||
3Toxicology and Pharmacology Department, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran | ||
4Clinical Research Development Unit of Shahid Beheshti Hospital, Hamadan University of Medical science, Hamadan, Iran | ||
چکیده | ||
Objective: Metabolic syndrome (MS) is a cluster of cardio-metabolic risk factors. MS is known as a highly prevalent disease worldwide. According to the existing evidence, consuming curcumin has positive effects on lipids profile, glucose, and body weight. This study aimed to evaluate the effects of nano-curcumin therapy on insulin resistance and serum level of afamin in patients with MS. Materials and Methods: Thirty MS patients (15 males and 15 females) received 80 mg/daily nano-curcumin for two months. The samples of fasting blood were collected from the participants at the beginning and 60 days after initiation of the intervention to measure biomarkers. Results: Comparing pre- and post-treatment with nano-curcumin values revealed a significant decrease in fasting plasma glucose (FPG) (p=0.017), insulin, homeostatic model assessment of insulin resistance (HOMA-IR) (p=0.006), and afamin (p=0.047). Moreover, there was a significantly negative relationship between afamin and high-density lipoprotein cholesterol (HDL-C) (p=0.044), as well as a significantly positive relationship between afamin and systolic (SBP) (p <0.001) and diastolic (DBP) (p <0.001) blood pressures. Conclusion: Results suggest that taking nano-curcumin for 60 days may have positive effects on afamin, FPG, insulin, and HOMA-IR in patients with MS, but would not significantly affect other metabolic profiles. More studies with larger sample sizes are required to confirm these findings. | ||
کلیدواژهها | ||
Nano-curcumin؛ Metabolic syndrome؛ Insulin resistance؛ Afamin | ||
مراجع | ||
Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. 2009. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation, 120:1640-1645. Almobarak AO, Jervase A, Fadl AA, Garelnabi NI, Al Hakem S, Hussein TM, Ahmad AA, El-den Ahmed IS, Badi S, Ahmed MH. 2020. Prevalence of diabetes and metabolic syndrome and associated risk factors in Sudanese individuals with gallstones: a cross sectional survey. TGH, 5. Azizi F, Khalili D, Aghajani H, Esteghamati A, Hosseinpanah F, Delavari A, et al.2010. Appropriate waist circumference cut-off points among Iranian adults: the first report of the Iranian National Committee of Obesity. Arch Iran Med, 13:243. Cornier M-A, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al.2008. The metabolic syndrome. Endocr Rev, 29:777-822. Dieplinger H, Dieplinger B. 2015. Afamin--A pleiotropic glycoprotein involved in various disease states. Clin Chim Acta, 446:105- 110. Du Q, Hu B, An HM, Shen KP, Xu L, Deng S, et al.2013. Synergistic anticancer effects of curcumin and resveratrol in Hepa1-6 hepatocellular carcinoma cells. Oncol Rep, 29:1851-1858. Ganugula R, Arora M, Jaisamut P, Wiwattanapatapee R, Jørgensen HG, Venkatpurwar VP, et al. 2017. Nano‐ curcumin safely prevents streptozotocin‐ Nano-curcumin reduced afamin in MS patients AJP, Vol. 11, No. 2, Mar-Apr 2021 153 induced inflammation and apoptosis in pancreatic beta cells for effective management of Type 1 diabetes mellitus. Br J Pharmacol, 174:2074-2084. Ghasemi H, Einollahi B, Kheiripour N, Hosseini-Zijoud SR, Farhadian Nezhad M.2019. Protective effects of curcumin on diabetic nephropathy via attenuation of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) expression and alleviation of oxidative stress in rats with type 1 diabetes. Iran J Basic Med Sci, 22:376-383. Hatamipour M, Sahebkar A, Alavizadeh SH, Dorri M, Jaafari MR. 2019. Novel nanomicelle formulation to enhance bioavailability and stability of curcuminoids. Iran J Basic Med Sci, 22:282- 289. Hosseinpanah F, Borzooei S, Farshadi M, Sarvghadi F, Azizi F. 2012. Diagnostic values of metabolic syndrome definitions for detection of insulin resistance: Tehran Lipid and Glucose Study (TLGS). Arch Iran Med, 15:606-610. Javandoost A, Afshari A, Saberi Karimian M, Sahebkar A, Safarian Bana H, Moammeri M, Fathi Dizaji B, Tavalaei S, A. A. Ferns G, Pasdar A, Parizadeh SM, Ghayour Mobarhan M. 2018. The effects of curcumin and a modified curcumin formulation on serum Cholesteryl Ester Transfer Protein concentrations in patients with metabolic syndrome: A randomized, placebocontrolled clinical trial. Avicenna J Phytomed, 8:330-337. Kintscher U, Law RE.2005. PPARgammamediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab, 288: E287-291. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C.2008. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens, 26:2064-2070. Ko N-Y, Lo Y-TC, Huang P-C, Huang Y-C, Chang J-L, Huang H-B. 2019. Changes in insulin resistance mediate the associations between phthalate exposure and metabolic syndrome. Environ Res, 175:434-441. Kollerits B, Lamina C, Huth C, Marques-Vidal P, Kiechl S, Seppala I, et al.2017. Plasma Concentrations of Afamin Are Associated With Prevalent and Incident Type 2 Diabetes: A Pooled Analysis in More Than 20,000 Individuals. Diabetes Care, 40:1386- 1393. Kronenberg F, Kollerits B, Kiechl S, Lamina C, Kedenko L, Meisinger C, et al. 2014. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet, 7:822-829. Lichenstein HS, Lyons DE, Wurfel MM, Johnson DA, McGinley MD, Leidli JC, et al. 1994. Afamin is a new member of the albumin, alpha-fetoprotein, and vitamin Dbinding protein gene family. J Biol Chem, 269:18149-18154. Nishiyama T, Mae T, Kishida H, Tsukagawa M, Mimaki Y, Kuroda M, et al.2005. Curcuminoids and sesquiterpenoids in turmeric (Curcuma longa L.) suppress an increase in blood glucose level in type 2 diabetic KK-Ay mice. J Agric Food Chem, 53:959-963. Rahimi HR, Mohammadpour AH, Dastani M, Jafari MR, Abnous K, Mobarhan MG, Kazemi Oskuee R. 2016. The effect of nanocurcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed, 6: 567-577. Seeber B, Morandell E, Lunger F, Wildt L, Dieplinger H.2014. Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. Reprod Biol Endocrinol, 12:88-95. Sharangi AB, Acharya S.2018. Spices in India and Beyond: The Origin, History, Tradition and Culture. Indian Spices: Springer,1-11. Wallace TM, Levy JC, Matthews DR. 2004. Use and abuse of HOMA modeling. Diabetes care, 27:1487-1495. Watson KE, Horowitz BN, Matson G. 2019. Lipid abnormalities in insulin resistant states. RCM. 25:228-36 Xu X-Y, Meng X, Li S, Gan R-Y, Li Y, Li HB.2018. Bioactivity, Health Benefits, and Related Molecular Mechanisms of Curcumin: Current Progress, Challen | ||
آمار تعداد مشاهده مقاله: 11,105 تعداد دریافت فایل اصل مقاله: 2,334 |